Experimental pancreatic cancer vaccine elicits durable immune responses in high-risk participants. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is often diagnosed at advanced stages and carries a low five-year survival rate.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is often diagnosed at advanced stages and carries a low five-year survival rate. Approximately 10% of cases are associated with hereditary predisposition caused by pathogenic mutations in specific cancer susceptibility genes that are passed down from parent to child.
- Ponto de atenção: experimental.
- Ponto de atenção: pancreatic.
- Ponto de atenção: cancer.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
:quality(85)/ab524158-b869-4395-b102-c51e4b840392.jpeg)